Enovis Corporation/$ENOV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Enovis Corporation

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Ticker

$ENOV
Sector

Primary listing

NYSE

Employees

7,367

ENOV Metrics

BasicAdvanced
$1.9B
-
-$14.68
1.81
-

Bulls say / Bears say

Second-quarter net sales rose 7% year-on-year to $565 million on a reported basis and 5% on an organic basis, reflecting continued commercial momentum in both Prevention & Recovery and Reconstructive segments (GlobeNewswire).
Management raised full-year 2025 revenue guidance to $2.245–2.275 billion and adjusted EBITDA guidance to $392–402 million, up from prior ranges, signaling confidence in sustainable growth (GlobeNewswire).
The Reconstructive segment delivered 11% reported and 8% organic growth in Q2 2025, driven by successful new product launches such as the ARG shoulder system and Nebula hip stem, underpinning segment leadership (Investing.com).
Enovis reported a net loss of $37 million in Q2 2025, equivalent to 6.5% of sales, extending its unprofitable GAAP position into the first half of the fiscal year (GlobeNewswire).
The company incorporates a $20 million EBITDA headwind from tariffs into its 2025 guidance, highlighting ongoing supply chain vulnerabilities and cost pressures in the Prevention & Recovery segment (GlobeNewswire).
Enovis posted a net loss of $56 million in Q1 2025, or 10.0% of sales, underscoring persistent profitability challenges despite sequential revenue and margin gains (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ENOV

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs